MTNB Chart
- 52-Week Range: $0.50 - $1.51
- Market Capitalization: $152.33M
- Short Percentage: 0%
- Target Price: $2.75
- Shares Outstanding: 216.86M
- Next Earnings: Nov 30
Catalysts
CategoryCatalyst
Earnings
MTNB released their earnings report for the previous quarter and provided guidance on the current and upcoming quarters.
News and Press Releases
- Matinas BioPharma (MTNB) CEO, Jerome Jabbour on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha | May 12th
- Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational HighlightsGlobeNewsWire | May 12th
- Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering ConferenceGlobeNewsWire | May 3rd
- Matinas BioPharma to Present at the Needham Virtual Healthcare ConferenceGlobeNewsWire | April 6th
- Matinas BioPharma Provides Business Update and 2022 Strategic OutlookGlobeNewsWire | January 25th
- Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022GlobeNewsWire | January 18th
- Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business OfficerGlobeNewsWire | December 6th
Company Info
Website: https://www.matinasbiopharma.com
Address: 1545 Route 206 South, Bedminster, NJ, United States, 07921
Sector: Healthcare
Industry: Biotechnology
Full time employees: 31
Address: 1545 Route 206 South, Bedminster, NJ, United States, 07921
Sector: Healthcare
Industry: Biotechnology
Full time employees: 31
$MTNB to the moon
$MTNB buying a share monday LFG
$MTNB To the moon!!
$MTNB back to business
$MTNB we finna be at the top yo
$MTNB Growth/Value
$MTNB oversold! Buy the dip
$MTNB Reinvest your dividends
$MTNB yeeeeeee haw
$MTNB hi hi